To select the appropriate pharmaceutical composition, we devised a method to express functional parts in vitro by usingour fusion protein part. For more info, please refer to ourParts page which we have completed before the deadline.
New Part Registration and existed part updating
We upload new data from references for old parts as recorded in our judging form, and we also upload 7 basic part and 4 composite part (BBa_K3672001~BBa_K3672010)
For these parts, we optimized their original sequences by referring to literatures, so as to enhance the expression efficiency and adaptability of the disease background.
These parts involve the blocking of key signal pathways in pulmonary fibrosis signal pathways, the identification and targeting of fibrosis lesions, etc.
These components, first reported in the iGEM community, will provide research convenience for future iGEMer participants, call attention to the treatment of fibrosis and pulmonary fibrosis patients, and maintain an open and friendly atmosphere in the iGEM community.
Cell-free methodology application for protein selection and iteration
We also expressed our proteins with cell-free expression system that has not been widely used by iGMEer. In vitro, protein expression system transcribes and translates target protein genes by transcriptional and translational systems constructed in vitro. Compared with traditional eukaryotic or prokaryotic chassis biological expression systems, it has significant advantages in drug development and protein design: researchers can quickly obtain protein samples that can be tested in vitro or even in small batches of animals.
From preparation system to complete protein expression only takes 1h. simulation. Besides, we can also provide guidance for wet experiment with the experimental prediction model.
The combination of cell-free protein expression system and dry experimental protein drug modeling provides a new idea of low cost and low time for rapid iteration test in early drug development.
Protein molecules are designed to be fully simulated and therapeutic efficacy as predicted. After that, protein samples were obtained rapidly by using cell-free protein expression system, and functional verification can be carried out in the early stage. Then wet experimental data can be compared and modified with the previous dry experimental data, and the protein design can be further optimized and adjusted.
The introduction of this concept will continue the development and design of protein-enabling drugs.
We have conducted business cooperation and discussion with Nanyi Huajun Company, and Nanyi Huajun company highly approves our design ideas, so we have obtained the exclusive sponsorship from Nanyi Huajun Company.
In the later stage, our team will further develop and apply this protein drug development model to promote the popularization of low-cost protein drug design scheme.We also want to leverage the open source platform of iGEM to share our ideas with iGEMer worldwide, which could be important for biomedical startups and small research groups.
Gastroplus innovative application for protein drugs selection
We used Gastroplus, which has never been applied in iGEM contest to design and simulate our proteins in vitro, so as to make full use of the period of staying at home phase in the COVID-19 epidemic for drug metabolism
We provide a model of drug metabolism in animals and humansusing database fitting, which will help other iGEMers to evaluate their drugs metabolism better.(more details in our model page)